|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Mar 30, 2009. Severance,
restructuring and other costs
During 2008, we incurred severance, restructuring and other
costs of $22.1 million related primarily to the realignment
of our commercial activities in Tysabri for CD and the
announced closure of our offices in New York and Tokyo, which
occurred in March 2009.
During 2007, we incurred severance, restructuring and other
costs of $32.4 million arising principally from the
restructuring of our commercial infrastructure and consolidation
of our U.S. West Coast locations, which resulted in the
closure of the San Diego facility and the expansion of our
operations in South San Francisco. The restructuring of our
commercial infrastructure was primarily a result of the approval
of a generic form of Maxipime and the anticipated
approval of a generic form of Azactam.
This excerpt taken from the ELN 20-F filed Feb 26, 2009. (a) Severance,
restructuring and other costs
During 2008, we incurred severance, restructuring and other
costs of $22.0 million related primarily to the realignment
of our commercial activities in Tysabri for CD and the
announced closure of our offices in New York and Tokyo, which is
to occur in the first half of 2009.
Table of Contents
During 2007, we incurred severance, restructuring and other
costs of $32.4 million arising principally from the
restructuring of our commercial infrastructure and consolidation
of our U.S. West Coast locations, which resulted in the
closure of the San Diego facility and the expansion of our
operations in South San Francisco. The restructuring of our
commercial infrastructure was primarily a result of the approval
of a generic form of Maxipime and the anticipated
approval of a generic form of Azactam.
During 2006, the net severance, restructuring and other costs of
$7.5 million were related to the realignment of our
resources to meet our business structure at that time. The
restructuring and severance charges in 2006 were primarily
related to the consolidation of our Biopharmaceuticals R&D
activities into our South San Francisco facility. These
charges arose from termination of certain operating leases,
reduction of headcount and relocation of employees, and they
also included the reversal of a $9.4 million charge for
future lease payments on an unutilized facility in South
San Francisco. As a part of the restructuring of our
Biopharmaceuticals R&D activities, this facility was
brought back into use.
This excerpt taken from the ELN 6-K filed Mar 31, 2008. Severance,
restructuring and other costs
During 2007, we incurred severance, restructuring and other
costs of $32.4 million arising principally from the
restructuring of our commercial infrastructure and consolidation
of our U.S. West Coast locations, which resulted in the
closure of the San Diego facility and the expansion of our
operations in South San Francisco. The restructuring of our
commercial infrastructure was primarily a result of the approval
of a generic form of Maxipime and the anticipated
approval of a generic form of Azactam.
During 2006, the severance, restructuring and other costs of
$7.5 million (comprised of other charges of
$2.5 million in cost of sales, other credits of
$4.9 million in SG&A expenses and other charges of
$9.9 million in R&D expenses) related to the
realignment of our resources to meet our current business
structure. The restructuring and severance charges in 2006 were
primarily related to the consolidation of our Biopharmaceuticals
R&D activities into our South San Francisco facility.
These charges arose from termination of certain operating
leases, reduction of headcount and relocation of employees, and
they included the reversal of a $9.4 million charge for
future lease payments on an unutilised facility in South
San Francisco. As a part of the restructuring of our
Biopharmaceutical R&D activities, this facility was brought
back into use.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. (B) Severance,
restructuring and other costs
During 2007, we incurred severance, restructuring and other
costs of $32.4 million arising principally from the
restructuring of our commercial infrastructure and consolidation
of our U.S. West Coast locations, which resulted in the
closure of the San Diego facility and the expansion of our
operations in South San Francisco. The restructuring of our
commercial infrastructure was primarily a result of the approval
of a generic form of Maxipime and the anticipated
approval of a generic form of Azactam. For additional
information regarding the activity related to the severance and
restructuring accruals, refer to Note 17.
During 2006, the net severance, restructuring and other costs of
$7.5 million were related to the realignment of our
resources to meet our current business structure. The
restructuring and severance charges in 2006 were primarily
related to the consolidation of our Biopharmaceuticals R&D
activities into our South San Francisco facility. These
charges arose from termination of certain operating leases,
reduction of headcount and relocation of employees, and they
include the reversal of a $9.4 million charge for future
lease payments on an unutilized facility in South
San Francisco. As a part of the restructuring of our
Biopharmaceutical R&D activities, this facility was brought
back into use.
During 2005, the severance, restructuring and other costs of
$11.8 million were due to the realignment of our resources
to meet our current business structure. These expenses arose
from termination of certain operating leases and a reduction in
employee headcount.
This excerpt taken from the ELN 20-F filed Feb 28, 2007. (B) Severance,
restructuring and other costs
During 2005, we incurred severance, restructuring and other
costs of $11.8 million arising from the realignment of our
resources to meet our current business structure. These expenses
arose from termination of certain operating leases and a
reduction in employee headcount.
During 2004, we incurred severance, restructuring and other
costs arising from the implementation of our recovery plan of
$3.8 million. The recovery plan, which commenced in July
2002 and was completed in February 2004, involved the
restructuring of our businesses, assets and balance sheet. These
expenses arose from a reduction in the scope of our activities
and a reduction in employee headcount.
Table of Contents
| EXCERPTS ON THIS PAGE:
|
| |||||||
